Celldex Therapeutics, Inc (NASDAQ:CLDX) Clinical Data Recalibrates Near‑Term Growth Trajectory
![]() |
Recent trial readouts and presentation timing shift the stock’s short‑term technical bias despite ample liquidity; fundamentals still show a high valuation relative to underlying revenue and profitability. Market reaction will hinge on upcoming Phase 3 readouts and how the broader program portfolio performs versus expectations. |










